Pefloxacin Mesylate for Injection

Pefloxacin mesylate is a quinolone antibacterial drug with a broad-spectrum antibacterial effect. It has good antibacterial effects on the following bacteria: most bacteria of the Enterobacteriaceae family, including Escherichia coli, Klebsiella, Proteus, Shigella, Typhoid and Salmonella, as well as Haemophilus influenzae and Neisseria. It also has a certain antibacterial effect on Pseudomonas aeruginosa and Staphylococcus aureus. It has only a mild effect on pneumococci, various groups of streptococci and enterococci. In addition, it also has antibacterial activity against Mycobacterium leprae. Pefloxacin mesylate is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibits the synthesis and replication of bacterial DNA, and causes bacterial death.

The main component of this product is pefloxacin mesylate. Chemical name: 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methylpiperazine-1-yl)-4-oxo-quinoline-3-carboxylic acid methanesulfonate. Molecular formula: C17H20FN3O3CH3SO3H2H2O. Molecular weight: 465.49.

This product is white freeze-dried block.

Various infections caused by pefloxacin-sensitive bacteria: urinary tract infections; respiratory tract infections; ear, nose and throat infections; gynecological and reproductive system infections; abdominal and liver and gallbladder system infections; bone and joint infections; skin infections; sepsis and endocarditis; meningitis.

Intravenous drip: Common adult dosage, 0.4g at a time, add to 250ml of 5% glucose solution and slowly drip intravenously, once every 12 hours. Patients with ascites should take the medicine once every 36 hours; patients with jaundice and ascites should take the medicine once every 48 hours. Or follow the doctor's advice.

1 Gastrointestinal reactions: nausea, vomiting, loss of appetite, diarrhea, etc. 2 Central nervous system reactions: dizziness, headache, drowsiness or insomnia, etc. 3 Allergic reactions: rash, skin itching, occasionally exudative, multiforme erythema and angioneurotic edema. A few patients have photosensitivity reactions. 4 Occasionally, the following may occur: ① epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors; ② interstitial nephritis manifestations such as hematuria, fever, and rash; ③ crystalluria, more common in high-dose applications; ④ joint pain. ⑤ local irritation symptoms at the injection site. 5 A small number of patients may experience elevated serum aminotransferase, increased blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

It is contraindicated for patients allergic to fluoroquinolones, pregnant and lactating women, patients under 18 years of age, and patients with 6-phosphate glucose dehydrogenase deficiency.

1 Urine alkalinizing agents can reduce the solubility in urine, leading to crystalluria and nephrotoxicity. 2 When used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver elimination of theophylline, a prolonged plasma elimination half-life (t1/2beta;), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc., and the co-use should be avoided. If it cannot be avoided, theophylline blood drug concentration should be measured and the dose adjusted. 3 When cyclosporine is used in combination with warfarin, its blood drug concentration increases. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4 When used in combination with the anticoagulant warfarin, the latter's anticoagulant effect can be enhanced. When used in combination, the patient's prothrombin time should be closely monitored and the dose adjusted. 5 Probenecid can reduce the secretion of drugs from the renal tubules by 50%. When used in combination, toxicity may occur due to increased blood concentration. 6. Interfere with the metabolism of caffeine, thereby reducing the elimination of caffeine, prolonging the blood elimination half-life (t1/2beta;), and possibly producing central nervous system toxicity. When used together, the patient's blood caffeine concentration should be closely monitored and the dosage adjusted.

Keep in a light-proof and airtight container.

0.2g

Zhejiang BETTER Pharmaceuticals Co., Ltd.

• Founded in:

  2004-11-10

• Address:

  Sanjiang Road, Paojiang Industrial Zone, Yuecheng District, Shaoxing City, Zhejiang Province

• Tax NO.:

  91330600765236277X

• Registered Funds:

  255.635685 yuan

• Website:

  Log in to view

• Email:

  Log in to view